- 29th Jul 2010
Excellent Website ranking in the Swiss Pharma Site Monitor - 8th Apr 2010
Biopartners Receives EU Marketing Authorization for Ribavirin Biopartners 200mg film-coated Tablet for Chronic Hepatitis C - 11th Jun 2009
Biopartners and LG Life Sciences Ltd present positive phase 3, placebo-controlled six month efficacy and safety data for sustained release recombinant human growth hormone (LB03002) given to adults with growth hormone deficiency - 5th Jun 2009
Biopartners Appoints Dr Conrad Savoy as CEO - 29th May 2009
Biopartners withdrew the Application for Marketing Authorisation for Biferonex® - 19th Feb 2009
Biopartners to appeal the CHMP’s negative opinion on its novel interferon beta-1a - 22nd Sep 2008
CEO Jean-Noël Treilles and CSO Dr Conrad Savoy talk about the company and products in a short video - 22nd Sep 2008
Biopartners presents three year safety and efficacy data for sustained release recombinant human growth hormone (LB03002) at ESPE 2008 - 20th Aug 2008
Biopartners to present 3-year safety and efficacy trial data for its once-a-week sustained release recombinant human growth hormone (SR-hGH; LB03002) at major scientific conferences - 20th Dec 2007
Biopartners terminates collaboration with The Medical House - 20th Aug 2007
Biopartners submits its novel interferon beta-1a, Biferonex®, to the EMEA - 14th Aug 2007
Clinical Phase III Trial Data Demonstrate Valtropin®’s Safety and Efficacy - 29th Mar 2007
Biopartners Appoints New CSO, Dr Conrad Savoy - 14th Mar 2007
Biopartners Holdings AG Purchased by Bioton S.A. - 30th Jun 2006
BioPartners remains positive after Alpheon® CHMP ruling - 4th May 2006
Biopartners Receives European Union Marketing Authorisation for its Biosimilar Recombinant Human Growth Hormone - Valtropin® - 24th Feb 2006
Biopartners Announces CHMP Positive Opinion for its biosimilar Recombinant Human Growth Hormone – Valtropin™
